Breaking News Instant updates and real-time market news.

MRK

Merck

$84.02

-1.59 (-1.86%)

, LLY

Eli Lilly

$111.50

-1.36 (-1.21%)

06:32
07/09/19
07/09
06:32
07/09/19
06:32

Judge blocks Trump regulation requiring drug prices in TV ads, WSJ reports

A federal judge sided with manufacturers on Monday to block a Trump administration regulation requiring drugmakers to put prices in television ads, saying the rule would violate free speech, The Wall Street Journal's Stephanie Armour reports. "But no matter how vexing the problem of spiraling drug costs may be, HHS cannot do more than what Congress has authorized," U.S. District Judge Amit Mehta wrote in his decision. "The responsibility rests with Congress to act in the first instance." The lawsuit was brought by Merck (MRK), Eli Lilly (LLY) and Amgen (AMGN). Reference Link

MRK

Merck

$84.02

-1.59 (-1.86%)

LLY

Eli Lilly

$111.50

-1.36 (-1.21%)

AMGN

Amgen

$182.26

-3.74 (-2.01%)

  • 16

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 09

    Sep

  • 16

    Sep

  • 20

    Sep

  • 02

    Oct

MRK Merck
$84.02

-1.59 (-1.86%)

07/03/19
07/03/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Gol Linhas (GOL) upgraded to Buy from Neutral at Goldman Sachs with analyst Bruno Amorim saying the suspension of Avianca Brasil's operations on May 24 should provide a "significant boost" to unit revenues in the Brazilian domestic market in upcoming quarters. 2. Cinemark (CNK) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould saying the "tough" comp facing the company in Q2 is now priced into the shares. 3. Latam Airlines (LTM) downgraded to Sell from Neutral at Goldman Sachs with analyst Bruno Amorim saying "fierce" competition in the Spanish speaking countries and "still weak" pricing in the international markets will likely offset the positive effect from Avianca Brasil's bankruptcy. 4. Inogen (INGN) downgraded to Underweight from Neutral at JPMorgan with analyst Robert Marcus, who continues to view Inogen as a "potentially attractive story" longer-term, saying he believes the company's near-term outlook is weighed down by uncertainty and market headwinds. 5. Merck (MRK) initiated with a Buy rating and a $97 price target at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/03/19
MZHO
07/03/19
INITIATION
Target $97
MZHO
Buy
Mizuho starts Merck with Buy rating, $97 price target
Mizuho analyst Mara Goldstein last night initiated coverage of Merck with a Buy rating and $97 price target. The company is larger than Keytruda, but the "drug is too big to ignore," Goldstein tells investors in a research note. She believes Merck can overcome the loss of exclusivity on its Januvia franchise given Keytruda's "dominance" in immuno-oncology. The latter will drive operating margin expansion over the next five years, contends Goldstein.
07/02/19
MZHO
07/02/19
INITIATION
Target $97
MZHO
Buy
Merck initiated with a Buy at Mizuho
Mizuho started Merck with a Buy rating and $97 price target.
06/21/19
BOFA
06/21/19
NO CHANGE
Target $96
BOFA
Buy
Merck price target raised to $96 from $91 at BofA/Merrill
BofA/Merrill Lynch analyst Jason Gerberry raised his price target on Merck shares to $96 from $91 following the company's investor day meeting, stating that management conveyed a slightly more bullish outlook on margins and key revenue growth drivers at the event. He now thinks Merck will achieve about 40% operating margins by 2023, up from his prior 37.5% view, and also raised his out-year Gardasil estimates and factored in V114 risk-adjusted peak sales at $0.8B following the meeting. Gerberry keeps a Buy rating on Merck shares.
LLY Eli Lilly
$111.50

-1.36 (-1.21%)

06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.
06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
05/30/19
WELS
05/30/19
NO CHANGE
WELS
U.S. generic data continues to show challenging environment, says Wells Fargo
Wells Fargo analyst David Maris says that according to April IQVIA data, Teva (TEVA) U.S. generic sales were down 19% in April year over year, while brands sales were down 15%. Additionally, according to IQVIA data, Teva recently ceded its second place U.S. prescription market share place to competitor Eli Lilly (LLY) for its migraine drug, Ajovy, he points out. For Mylan (MYL), Maris says the monthly trends also paint a negative picture, with IQVIA U.S. generic sales in April down 36%. Nonetheless, the analyst believes Teva and Mylan shares seem to be reflecting an "aggressively negative outlook" given the current earnings multiples, and setting aside the worst-case outcomes in the opioid and price fixing cases, these may be at or nearing attractive valuations. However, for now, he remains on the sidelines, and within generics, continues to recommend Outperform-rated Amphastar (AMPH).
05/28/19
GSCO
05/28/19
INITIATION
Target $135
GSCO
Buy
Eli Lilly initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Eli Lilly with a Buy rating and $135 price target. The company has new product cycles in four large and growing therapeutic categories - diabetes, cancer, pain and immunology, Flynn tells investors in a research note. He believes investors are underappreciating Eli Lilly's longer-term growth potential in diabetes.
AMGN Amgen
$182.26

-3.74 (-2.01%)

06/07/19
GUGG
06/07/19
DOWNGRADE
GUGG
Neutral
Guggenheim downgrades Mirati to Neutral following near-tripling of stock
As previously reported, Guggenheim analyst Michael Schmidt downgraded Mirati Therapeutics (MRTX) to Neutral from Buy, noting that the shares have nearly tripled since data were presented at the European Society for Medical Oncology, or ESMO, meeting in October. While Schmidt said Amgen's (AMGN) KRAS inhibitor Phase I data presented at the American Society of Clinical Oncology meeting validates MRTX849's potential mechanism of action, he sees a "lot of upside" priced in at the current valuation despite the remaining development risks. He also believes investor expectations have significantly increased ahead of Mirati's own Phase I data presentation in the second half of the year.
06/05/19
HCWC
06/05/19
NO CHANGE
Target $117
HCWC
Buy
Mirati Therapeutics price target raised to $117 from $84 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Mirati Therapeutics (MRTX) to $117 from $84 saying the positive data for Amgen's (AMGN) AMG 510 bode well for Mirati's MRTX849. The analyst believes the AMG 510 data "somewhat derisks" the development of MRTX849/ He raised his estimate for probability of success for MRTX849 to 20% from 10% and keeps a Buy rating on Mirati Therapeutics.
06/05/19
LEHM
06/05/19
NO CHANGE
Target $123
LEHM
Overweight
Mirati Therapeutics price target raised to $123 from $85 at Barclays
Barclays analyst Gena Wang raised her price target for Mirati Therapeutics (MRTX) to $123 from $85 saying Amgen's (AMGN) AMG510 data support KRAS G12C as a validated target, and the "impressive" data provide proof of concept for potentially single agent activity in non-small cell lung cancer. The analyst continues to believe that Mirati's MRTX849 could have a more favorable profile based on the preclinical results, including "longer half-life and good tissue penetration." She reiterates an Overweight rating on Mirati Therapeutics.
06/04/19
RHCO
06/04/19
NO CHANGE
Target $120
RHCO
Buy
Mirati Therapeutics price target raised to $120 from $85 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Mirati Therapeutics (MRTX) to $120 and kept his Buy rating following yesterday's "encouraging" ASCO presentation by Amgen (AMGN) regarding its KRAS G12C inhibitor AMG 510. The analyst notes that the side effect profile and response to the treatment's lowest dose in AMG 510 are positive for Mirati's MRTX849, raising his probability Adjusted Peak Sales for the latter to $1.65B from $1.33B with probability of success little changed at 52%.

TODAY'S FREE FLY STORIES

ASOMY

Asos

$0.00

(0.00%)

21:13
07/21/19
07/21
21:13
07/21/19
21:13
Downgrade
Asos rating change at JPMorgan »

Asos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$131.95

-1.5 (-1.12%)

21:12
07/21/19
07/21
21:12
07/21/19
21:12
Upgrade
KLA-Tencor rating change at Goldman Sachs »

KLA-Tencor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

LRCX

Lam Research

$198.43

0.19 (0.10%)

21:07
07/21/19
07/21
21:07
07/21/19
21:07
Upgrade
Lam Research rating change at Goldman Sachs »

Lam Research upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MRVL

Marvell

$25.90

-0.48 (-1.82%)

21:07
07/21/19
07/21
21:07
07/21/19
21:07
Downgrade
Marvell rating change at Goldman Sachs »

Marvell downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$47.79

-0.38 (-0.79%)

21:05
07/21/19
07/21
21:05
07/21/19
21:05
Upgrade
Applied Materials rating change at Goldman Sachs »

Applied Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$45.51

0.85 (1.90%)

21:04
07/21/19
07/21
21:04
07/21/19
21:04
Upgrade
Goldman Sachs more positive on memory stocks, upgrades Micron to Buy »

Goldman Sachs analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEYS

Keysight Technologies

$87.43

0.05 (0.06%)

20:49
07/21/19
07/21
20:49
07/21/19
20:49
Downgrade
Keysight Technologies rating change at Goldman Sachs »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYND

Beyond Meat

$176.65

6.28 (3.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

19:30
07/21/19
07/21
19:30
07/21/19
19:30
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

BYND

Beyond Meat

$176.65

6.28 (3.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

DIS

Disney

$139.86

-1.76 (-1.24%)

NFLX

Netflix

$315.10

-10.04 (-3.09%)

T

AT&T

$32.77

-0.32 (-0.97%)

CBS

CBS

$50.68

-0.66 (-1.29%)

FDX

FedEx

$167.08

1.69 (1.02%)

EFX

Equifax

$137.29

-2 (-1.44%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

V

Visa

$179.18

-1.34 (-0.74%)

PYPL

PayPal

$118.65

-1.22 (-1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 12

    Aug

  • 21

    Aug

  • 29

    Aug

  • 17

    Sep

  • 19

    Sep

  • 25

    Sep

  • 16

    Oct

  • 13

    Nov

T

AT&T

$32.77

-0.32 (-0.97%)

, CMCSA

Comcast

$44.06

-0.5 (-1.12%)

18:23
07/21/19
07/21
18:23
07/21/19
18:23
On The Fly
Box Office Battle: 'The Lion King' roars to number 1 in $185M U.S. debut »

"Box Office Battle" is…

T

AT&T

$32.77

-0.32 (-0.97%)

CMCSA

Comcast

$44.06

-0.5 (-1.12%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$53.68

-0.275 (-0.51%)

LGF.A

Lionsgate

$11.94

0.36 (3.11%)

DIS

Disney

$139.86

-1.76 (-1.24%)

VIAB

Viacom

$30.48

-0.11 (-0.36%)

VIA

Viacom

$35.24

0.24 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

EFX

Equifax

$137.29

-2 (-1.44%)

17:23
07/21/19
07/21
17:23
07/21/19
17:23
Periodicals
Equifax agrees to pay $700M after massive data breach, WSJ reports »

Equifax is nearing a deal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 06

    Aug

  • 12

    Aug

  • 13

    Nov

CBS

CBS

$50.68

-0.66 (-1.29%)

, T

AT&T

$32.77

-0.32 (-0.97%)

17:17
07/21/19
07/21
17:17
07/21/19
17:17
Periodicals
AT&T drops CBS channels from cable systems, Reuters reports »

CBS (CBS) and AT&T…

CBS

CBS

$50.68

-0.66 (-1.29%)

T

AT&T

$32.77

-0.32 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

  • 08

    Aug

NFLX

Netflix

$315.10

-10.04 (-3.09%)

17:11
07/21/19
07/21
17:11
07/21/19
17:11
Periodicals
Netflix signs first direct agreement with SAG-AFTRA, Bloomberg reports »

Netflix and the Screen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

17:08
07/21/19
07/21
17:08
07/21/19
17:08
Periodicals
Johnson & Johnson facing key test in talc-safety lawsuits, WSJ reports »

Johnson & Johnson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

MRKR

Marker Therapeutics

$6.28

-2.4 (-27.65%)

16:46
07/21/19
07/21
16:46
07/21/19
16:46
Hot Stocks
Marker Therapeutics reports interim results of MultiTAA T Cell Therapy »

Marker Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 09

    Sep

RDY

Dr. Reddy's

$37.73

-0.6 (-1.57%)

16:41
07/21/19
07/21
16:41
07/21/19
16:41
Hot Stocks
Dr. Reddy's announces transaction closure to divest Zembrace Symtouch, Tosymra »

Dr. Reddy's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

KLAC

KLA-Tencor

$131.95

-1.5 (-1.12%)

16:37
07/21/19
07/21
16:37
07/21/19
16:37
Upgrade
KLA-Tencor rating change at Goldman Sachs »

KLA-Tencor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

LRCX

Lam Research

$198.43

0.19 (0.10%)

16:33
07/21/19
07/21
16:33
07/21/19
16:33
Upgrade
Lam Research rating change at Goldman Sachs »

Lam Research upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MRVL

Marvell

$25.90

-0.48 (-1.82%)

16:30
07/21/19
07/21
16:30
07/21/19
16:30
Downgrade
Marvell rating change at Goldman Sachs »

Marvell downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEYS

Keysight Technologies

$87.43

0.05 (0.06%)

16:29
07/21/19
07/21
16:29
07/21/19
16:29
Downgrade
Keysight Technologies rating change at Goldman Sachs »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$45.51

0.85 (1.90%)

16:26
07/21/19
07/21
16:26
07/21/19
16:26
Upgrade
Micron rating change at Goldman Sachs »

Micron upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.